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Abstract
Canonical ubiquitin-like proteins (UBLs) such as ubiquitin, Sumo, NEDD8, and ISG15 are ligated to targets by E1-E2-E3
multienzyme cascades. The Sumo cascade, conserved among all eukaryotes, regulates numerous biological processes
including protein localization, transcription, DNA replication, and mitosis. Sumo conjugation is initiated by the
heterodimeric Aos1-Uba2 E1 enzyme (in humans called Sae1-Uba2), which activates Sumo’s C-terminus, binds the
dedicated E2 enzyme Ubc9, and promotes Sumo C-terminal transfer between the Uba2 and Ubc9 catalytic cysteines. To
gain insights into details of E1-E2 interactions in the Sumo pathway, we determined crystal structures of the C-terminal
ubiquitin fold domain (ufd) from yeast Uba2 (Uba2
ufd), alone and in complex with Ubc9. The overall structures of both yeast
Uba2
ufd and Ubc9 superimpose well on their individual human counterparts, suggesting conservation of fundamental
features of Sumo conjugation. Docking the Uba2
ufd-Ubc9 and prior full-length human Uba2 structures allows generation of
models for steps in Sumo transfer from Uba2 to Ubc9, and supports the notion that Uba2 undergoes remarkable
conformational changes during the reaction. Comparisons to previous structures from the NEDD8 cascade demonstrate that
UBL cascades generally utilize some parallel E1-E2 interaction surfaces. In addition, the structure of the Uba2
ufd-Ubc9
complex reveals interactions unique to Sumo E1 and E2. Comparison with a previous Ubc9-E3 complex structure
demonstrates overlap between Uba2 and E3 binding sites on Ubc9, indicating that loading with Sumo and E3-catalyzed
transfer to substrates are strictly separate steps. The results suggest mechanisms establishing specificity and order in Sumo
conjugation cascades.
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Introduction
Post-translational modification by ubiquitin-like proteins (UBLs)
is a major mechanism for regulating eukaryotic protein functions.
UBLs generally become covalently attached to specific targets
through a series of molecular ‘‘handoffs’’ involving multienzyme
cascades consisting of an E1 activating enzyme, an E2 conjugating
enzyme, and an E3 ligase (reviewed in [1]). Thus, it is of great
interest to understand how E1, E2, and E3 enzymes interact with
each other for UBL transfer.
Like other ubiquitin-like proteins (UBLs), the Small ubiquitin-
related modifier (Sumo) proteins become covalently ligated to
targets (reviewed in [2,3,4]). Attachment of Sumo family UBLs are
known to alter target functions such as protein-protein interac-
tions, protein-DNA interactions, and subcellular localization
(reviewed in [5]). As such, Sumo regulates many important
processes, such as signaling, transcription, DNA repair and other
stress responses, the cell cycle, and apoptosis [2,3,4]. Indeed, the
budding yeast Smt3 protein (for simplification referred to as Sumo
hereafter) regulates chromosome segregation, formation of the
septin ring, and many other aspects of cell division [6,7,8].
Sumo family members are ligated to proteins via specific E1, E2,
and E3 enzymes. The Sumo-specific E1 enzyme [the heterodimeric
complex between Uba2 and Aos1 (yeast; termed Sae1-Uba2 in
mammals)] initiates the process by first catalyzing adenylation of the
Sumo C-terminus, which next becomes linked by a thioester bond
to Uba2’s catalytic cysteine [9,10,11,12]. A transthiolation reaction
ensues during which Sumo is transferred from Uba2 to the catalytic
cysteine of the dedicated Sumo E2 conjugating enzyme, Ubc9
[13,14,15,16]. Ultimately, either with or without facilitation by a
Sumo-pathway-specific E3, Sumo is transferred from the Ubc9
catalytic cysteine to a target lysine ([17] and references therein). In
some cases, repeated cycles of Sumo transfer lead to generation of
polySumo chains on targets (for review, see [18]). In recent years,
structural studies have provided details for many aspects of Sumo
E1-E2-E3 conjugation cascades. These include structural under-
standings of how human Sumo is recognized and activated by Sae1-
Uba2 [19,20], how Ubc9 recognizes targets [17,21,22,23], and how
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less, many fundamental aspects of the Sumo cascade remain
incompletely understood.
For example, how does the Sumo E1 bind Ubc9? The structure
of the human heterodimericSae1-Uba2 complexthat comprisesthe
Sumo E1 [19] displays conserved E1 domains [27,28]: a
heterodimeric ‘‘adenylation’’ domain comprised of portions of both
Sae1 and Uba2, a domain of Uba2 containing the E1 catalytic
cysteine, and a C-terminal ubiquitin-fold domain (ufd) from Uba2
that structurally resembles ubiquitin and Sumo [29]. For human
Uba2, the catalytic cysteine domain has been shown to make weak
interactions with Ubc9 [30]. In addition, for both yeast and human
Uba2, the ufd has been implicated in Ubc9 recruitment.
For canonical UBL pathways, E2s generally appear to bind an
E1 ufd [29]. Indeed, crystal structures from the pathway of
another UBL, NEDD8, showed previously that the NEDD8 E1’s
ufd binds NEDD8 E2s, either Ubc12 (also known as UBE2M) or
UBE2F, via the E2 N-terminal helix and b1b2-loop [31,32,33].
These E1
ufd-E2 interactions appear to be conserved across the
Sumo, NEDD8, ISG15 and ubiquitin pathways [29]. For
example, replacing the UBA6 or UBA7 ufds with that of UBA1
was sufficient to swap E2 specificities, and substituting the E2
UbcH7’s N-terminal helix and b1b2-loop regions with that of the
E2 UbcH8 swaps E1 specificity [34,35]. In terms of the Sumo
pathway, the human Uba2 ufd was also shown to bind Ubc9 and
to play an essential role in human Sae1-Sae2-mediated Sumo
transfer to Ubc9 [19,36]. The ufd of yeast Uba2 is essential for
viability [19]. And from the E2 side, budding yeast Ubc9’s N-
terminal helix and b1b2-loop were also shown to be important for
binding to Uba2 and formation of a Ubc9,Sumo complex [37].
Notably, the Ubc9 b1b2-loop is significantly extended relative to
other E2s, and has long been recognized as a unique structural
feature of Ubc9 [38,39]. Nonetheless, there is no high-resolution
data for E1
ufd-E2 interactions other than those for the NEDD8
pathway, despite their importance for the Sumo cascade in
particular and UBL transfer in general. Therefore, to obtain a
more detailed understanding of Uba2’s ufd interactions with Ubc9
and to obtain broad insights into how E1-E2 specificity is
established in general, we performed structural analysis of the
Uba2
ufd-Ubc9 complex from S. cerevisiae.
Results and Discussion
Structure of an isolated ubiquitin-fold domain from Uba2
(Uba2
ufd)
To characterize a domain from yeast Uba2 that binds Ubc9, we
determined the crystal structure of the isolated yeast Uba2
ubiquitin-fold domain (ufd), corresponding to residues 439–563,
at 1.6 A ˚ resolution (Table 1, Figure S1, Figure 1). For the most
part, residues 440–551 were clearly visible in the electron density
with all secondary structures well-defined and for consistency
numbered here according to their counterparts in the prior
structures of full-length human Uba2 [19]. Only a loop
encompassing residues 531–540 displayed weaker electron density
precluding building of several side-chains and resulting in high B-
factors, presumably due to greater flexibility.
Like ubiquitin and Sumo, the Uba2
ufd adopts a modified b-
grasp fold. Uba2
ufd consists of a twisted 5-stranded antiparallel b-
sheet on one side, one 3-turn a-helix on the opposite side of the
sheet, and two peripheral short helices. The b-sheet and
connecting loops form one V-shaped surface. A second V-shaped
surface comes from the edge of b-strand 23, the following loop,
and a-helix37. The two V-like structures are adjacent to each
other, and together form a W-shaped surface (Figure S2).
Structure of a Uba2
ufd-Ubc9 complex
In order to understand E1-E2 interactions in a Sumo pathway,
we determined the crystal structure of a Uba2
ufd-Ubc9 complex
from yeast. Phases were obtained by molecular replacement, using
the prior structure of yeast Ubc9 and a polyalanine model of
human Uba2 residues 449–546 as searchmodels [19,40]. There
are two molecules per asymmetric unit, which superimpose with
0.3 A ˚ root mean square deviation (rmsd) over all alpha carbons, so
only one version of the complex is discussed here. The structure of
the Uba2
ufd is nearly identical in the complex as on its own (0.47 A ˚
rmsd). The structure of Ubc9 superimposes well with the prior
structure of free Ubc9 (0.55 A ˚ rmsd), with the most notable
difference being slight variation in the position of the b1b2-loop.
The Uba2
ufd-Ubc9 complex adopts an overall oblong elliptical
shape, with the W-shaped surface from Uba2
ufd binding the N-
terminal a-helix1 and b1b2-loop from Ubc9 (Figure 1, Figure
S2). This interaction is distal - ,30 A ˚ – to the Ubc9 catalytic
cysteine. The Uba2





ufd-Ubc9 interface is interdigitated, with the two V-
shaped grooves from Uba2 binding alternating regions of Ubc9, as
in a layered sandwich. The ‘‘V’’ corresponding to the concave
Uba2
ufd b-sheet holds the Ubc9 N-terminal a-helix1 along its
entire length (Figure 2A). Ubc9’s Leu6 is loosely surrounded by a
hydrophobic surface from Uba2’s Leu478, Leu485, and Leu511
from three distinct strands. The remainder of the interaction is
largely ionic (Figure 2A). The Ubc9 N-terminus forms a
hydrogen bond with Uba2’s Gln483. Ubc9’s Gln10 makes a
hydrogen bond with Uba2’s Ser476 and Glu515. Ubc9’s Arg13
makes salt bridges with Uba2’s Asp488 and Asp490, and along
with Ubc9’s Lys14 interacts with Uba2’s Tyr489. Ubc9’s Lys14
and Arg17 interact with Uba2’s Asp474 and Asp490, respectively.
At the C-terminus of Ubc9’s a-helix1, Lys18 forms a hydrogen
bond with the backbone oxygen from Uba2’s Gly517.
The Ubc9 b1b2-loop straddles the Uba2 b-strand23. The tip of
the Ubc9 b1b2-loop fits in the second ‘‘V’’ shaped groove
generated by Uba2 b-strand23, a-helix37, and the intervening
loop. Ubc9’s Lys30 from one face of the b1b2-loop forms a salt-
bridge with Uba2’s Asp493. On the other side, Ubc9’s Asp33
interacts with Uba2’s Arg484. Ubc9’s Met36 and Leu38, at the C-
terminus of the b1b2-loop, pack against a hydrophobic ridge
comprising Uba2’s Leu478, Leu485, and Phe491 in the first ‘‘V’’.
The structure helps explain the deleterious effects of previously
reported mutants in yeast Ubc9, which showed that residue
substitutions in place of Lys14, or a combination of Lys14, Arg17,
and Lys18 from the N-terminal helix, or deleting a portion of the
b1b2-loop, hinders binding to full-length Aos1-Uba2 [37]. We
further tested the effects of mutating additional key interface
residues.Consistentwiththestructure,individualAlasubstitutionsin
place of Ubc9’s Arg13, Met36, or Leu38 hinders Aos1-Uba2-
mediated generation of a Ubc9,Sumo complex (Figure 2B,
Figure S3). Similar results are observed for mutating the key acidic
pa t chre si du esAs p4 8 8an d49 0fr omUb a 2( Figure2B,FigureS3).
Conservation of Ubc9 and Uba2 interacting residues
across species
Several structural features and individual amino acids involved
in the Uba2
ufd-Ubc9 interaction are conserved among Ubc9s and
Uba2s from yeast to humans. Yeast and human Ubc9 share 56%
sequence identity (Figure 1D). Accordingly, the Uba2-binding
side-chains from the Ubc9 a-helix1 are 100% conserved as basic
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but is uniquely extended relative to E2s for other UBLs. Here,
Asp33 is conserved as acidic, and Met36 and Leu38 are conserved
as hydrophobics.
The sequence similarity is reflected by extensive structural
similarity between yeast and human Ubc9 (0.53 A ˚ Ca rmsd,
previously noted for other structures in [40]). While the many
Ubc9 structures, from different organisms and in different
complexes, do generally superimpose well, the primary site of
very minor differences is in the orientation of the b1b2-loop. It is
possible that limited flexibility of this unique Ubc9 structure may
play a role in binding to the Uba2 ufd.
The sequences between Uba2 ufds are generally less conserved
(Figure 1E, Figure 3A, Figure 3B). Despite only 17% sequence
identity, a search of the Protein Data Bank using DALI identifies
the ufd region from a prior structure of full-length human Uba2
(also called Sae2) as having the highest degree of structural
similarity with the yeast Uba2
ufd (Ca rmsd 1.85 A ˚) [19,20,42].
The main differences are localized to two regions, which are distal
to the Ubc9-binding site. The first difference is the short a-
helix36a, which corresponds to an insertion in the sequence of
yeast Uba2 between b-strand21 and a-helix 36 (Figure 1E,
Figure 3A, Figure 3B). The second is at the C-terminal portion
of the domain where the sequences are most divergent: the loop
preceding b-strand24, the loop between b-strands24 and 25, and
the region following b-strand25 that is disordered in human Uba2
but in the yeast Uba2
ufd is ordered and forms a more extended
structure. Nonetheless, the striking similarity of the overall
structures of yeast and human Uba2 ufds supports the notion
that the structurally observed yeast Uba2
ufd-Ubc9 interactions will
be preserved across species. Indeed, some key interface residues
are relatively conserved, including Ser476 (Ser or Asp across
species), Arg484 (charged or polar), Leu485 (Leu, Ile, or Val across
species), and Asp488 and Asp490 (Ser or Asp, and Asp or Glu




Accession codes 3ONH.pdb 3ONG.pdb
Data collection
Beamline ALS 8.2.1 SERCAT ID
Wavelength (A ˚) 1.00000 1.00000
Space group I4 P21
Cell dimensions
a, b, c (A ˚) a=b=80.198, c=50.733 a=38.465,b=134.038, c=62.012
a, b, c (u) a=b=c=90 a=90, b=94.44, c=90
Resolution (A ˚) 50–1.6(1.66–1.6) 45–2.3(2.38–2.30)
Total reflections 289011 334522
Unique reflections 21034 24002
Rmerge (%) 9.9(58.6) 5.6(26.0)
Average I/s 17.8(3.0) 28.3(3.5)
Completeness (%) 98.8(96.4) 85.0(53.5)
Redundancy 2.9(2.8) 3.5(2.9)
Wilson B-factor 15.44 48.9
Refinement
Resolution range (A ˚) 40–1.6 38.4–2.3
No. of reflections (s$0) 20193 21393
Rwork (%) 16.0 22.3
Rfree (%) 17.8 25.1
Number of protein atoms 885 4267
Number of waters 81 38
Average B-factor (protein) 21 72
Average B-factor (water) 30 61
RMSD:
Bond lengths (A ˚) 0.006 0.007
Bond angles (u) 0.98 1.08
Ramachandran plot statistics
Residues in preferred regions (%) 92.8 90.3
Residues in additional allowed regions (%) 6.3 9.7
Residues in disallowed regions (%) 0.9 0
Highest resolution shell is shown in parenthesis. Rwork = g|Fo–Fc|/gFo. Rfree is the cross-validation of R-factor, with .5% of the total reflections omitted during model
refinement.
doi:10.1371/journal.pone.0015805.t001
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Ubc9 was shown to cause chemical shift perturbations in the
corresponding region of human Uba2
ufd [36].
Comparison of Uba2
ufd-Ubc9 with prior E1ufd structures
from other UBL pathways
To gain insights into similarities and differences among E1
ubiquitin-fold domains, we compared the yeast Uba2
ufd–Ubc9
crystal structure with the corresponding regions of crystal
structures of yeast Uba1 (E1 for ubiquitin) and human Uba3 (E1
for NEDD8) (Figure 3A, Figure 3C, Figure 3D, Figure S4).
The yeast Uba2
ufd displays overall structural similarity to the ufds
from Uba1 and Uba3 (2.4 and 1.6 A ˚ rmsd, respectively), including
the W-shaped surface. Furthermore, structural comparison of
Uba2
ufd-Ubc9 with prior structures of Uba3 in complex with
NEDD8 E2s (Ubc12 or UBE2F) reveal that the Sumo and
NEDD8 pathways use parallel E1
ufd and E2 surfaces to mediate
interactions (Figure 3E, Figure 3F).
Despite their overall common mode of binding, an intriguing
difference is that the relative positions of the E1
ufd and E2 catalytic




ufd–UBE2F (Figure 3E, Figure 3F).
The detailed interactions between Uba2 and Ubc9 described
above (Figure 2A) also differ substantially from corresponding
contacts in the NEDD8 pathway [31,33]. Furthermore, global
structural differences between Uba2 and other E1 ufds, and
between Ubc9 and other E2s help explain why Ubc9 does not
bind E1s for other UBLs and vice-versa. In the Uba1 ufd the
region corresponding to the Uba2
ufd’s short a-helix37 is extended
by a complete turn, and the preceding loop in Uba2
ufd
corresponds to a 2-turn helix in Uba1 (Figure 3C) [28]. This
latter helix is even longer in Uba3’s ufd (Figure 3D) [27,31].
These Uba1 and UBA3 helical insertions would clash with the
Uba2-binding basic residues from Ubc9’s a-helix1 and extended
b1b2 loop. Thus, several structural differences between E1
ufds,
and corresponding distinctions between their cognate E2s, may
help establish specificity of E1-E2 interactions.
Docking Uba2
ufd-Ubc9 onto prior full-length human
Aos1-Uba2 structures
In order to gain insights into Sumo transfer from Uba2 to Ubc9,
we superimposed the Uba2
ufd-Ubc9 structure onto the corre-
Figure 2. Details of the Uba2
ufd-Ubc9 interface. (A) Close-up viewofthe interface between Uba2
ufd and Ubc9. Uba2
ufd isshown inmagenta. Ubc9
isshownincyan.Nitrogens arecoloredblue. Oxygens arecoloredred.Electrostatic interactionsareindicatedwithdashes.(B) EffectsofmutationsinUb a2
or Ubc9 at the structurally-observed interface. Shown are autoradiograms monitoring
32P-labeled yeast Sumo, for time-courses of Aos1-Uba2-catalyzed
generation of Ubc9, [
32P]-Sumo thioester conjugate. The wild-type (WT) or mutant version of Uba2 or Ubc9 used in each panel is indicated above.
doi:10.1371/journal.pone.0015805.g002
Figure 1. Overall structure of the Uba2
ufd-Ubc9 complex. (A) Cartoon view of the overall structure of the complex with secondary structures
numbered as previously described [19,38,39]. Uba2
ufd is shown in magenta. Ubc9 is shown in cyan. (B) Superposition of free Uba2
ufd (pink)
superimposed with the Uba2
ufd-Ubc9 complex. (C) Superposition of free Ubc9 (seafoam) [40] with the Uba2
ufd-Ubc9 complex. (D) Sequence
alignment of Saccharomyces cerevisiae Uba2
ufd sequence (Sc), with the corresponding regions of Uba2 from human (Hs), Xenopus laevis (Xl),
Drosophila melanogaster (Dm), Kluyveromyces lactis (Kl), Schizosaccharomyces pombe (Sp), and Danio rerio (Dr). Alignment was made based on the
structures of S. cerevisiae Uba2
ufd described herein, and the prior structures of human Uba2 [19,20]. Sequence identity to S. cerevisiae Uba2 is
highlighted in magenta, and similarity is highlighted in pink, with residues contacting Ubc9 indicated with a cyan bar. Secondary structures are
indicated above. (E) Sequence alignment of Saccharomyces cerevisiae Ubc9 sequence (Sc), with the corresponding regions of Ubc9 from human (Hs),
Xenopus laevis (Xl), Drosophila melanogaster (Dm), Kluyveromyces lactis (Kl), Schizosaccharomyces pombe (Sp), and Danio rerio (Dr). Sequence identity
to S. cerevisiae Ubc9 is highlighted in blue, with residues contacting Uba2
ufd indicated with a magenta bar. Secondary structures are indicated above.
doi:10.1371/journal.pone.0015805.g001
Structural Insights into Sumo E1-E2 Interactions
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15805sponding region of human Uba2 from several recent crystal
structures [19,20]. The overall locations of domains, including the
ufd, are generally similar in structures of human Aos1-Uba2-
MgATP (also called Sae1-Sae2-MgATP, 1Y8Q.pdb), Aos1-Uba2-
Sumo-MgATP (1Y8R.pdb), and Aos1-Uba2-Sumo,AMSN (a
chemical modification mimicking Sumo C-terminal adenylation,
3KYC.pdb) [19,20]. The ufd is also in a similar relative
orientation in a recent structure of human Aos1-Uba2,Su-
mo,AVSN, which mimics the tetrahedral intermediate during
Uba2’s catalytic cysteine’s attack on the C-terminally adenylated
Sumo (3KYD.pdb), so only the comparison to Aos1-Uba2-
Sumo,AMSN is shown in Figure 4A. All the structures of full-
length Uba2 lack Ubc9, and represent states of Aos1-Uba2 prior
to Sumo transfer to Ubc9 [19]. All docking models on full-length
Uba2 would place Ubc9’s catalytic cysteine distal to and facing the
opposite direction of Uba2’s catalytic cysteine (Figure 4A).
To address the possibility of whether Sumo thioester-linked to
the catalytic Cys177 of one Uba2 can be transferred to Ubc9
bound to another Uba2, we examined generation of the
Ubc9,Sumo thioester-linked conjugate upon mixing two defec-
tive mutant versions of the Sumo E1. In one mutant, the Uba2
catalytic Cys177 was mutated to Ala to prevent formation of a
Uba2,Sumo intermediate, but the ufd was wild-type. The other
retained ability to form a thioester linkage with Sumo at Cys177,
but harbored Ala mutations in the Ubc9-binding ufd residues
Asp488 and Asp490. On their own, each mutant is defective for
generating the thioester-linked Ubc9,Sumo conjugate. Mixing
the two E1s does not rescue the other’s defect (Figure 4B).
Thus, it seems likely that Uba2 undergoes a conformational
change to bring the Uba2 and Ubc9 catalytic cysteines together for
Sumo transfer. Previous structural studies of the NEDD8 E1,
which showed dramatic ufd reorientation, may provide some
insights into such a conformational change. Superimposing
Uba2
ufd-Ubc9 on the Uba3
ufd in a structure of the NEDD8 E1
complexed with two molecules of NEDD8 and a catalytically-
inactive E2 (Ubc12), which represents an intermediate en route to
UBL transfer from E1 to E2, shows how ufd rotation might allow
Ubc9 to be reoriented toward Uba2’s catalytic cysteine [32].
However, even upon rotation of the Uba2 ufd to the position
observed in the NEDD8 E1, a significant E1-to-E2 cysteine-to-
cysteine gap remains (Figure 4C). It is possible that Uba2’s ufd
undergoes an even greater rotation during Sumo transfer. Another
excellent possibility for how the gap between the Uba2 and Ubc9
catalytic cysteines could be closed comes from the recent landmark
finding that the Uba2 catalytic cysteine domain can undergo
dramatic reorientation and remodeling [20]. It seems likely that
the proposed combination of ufd and catalytic cysteine domain
rotations bring the Uba2 and Ubc9 cysteines together.
Implications for E1-E2-E3 cascades in the Sumo pathway
E2s play the central role in UBL cascades. Thus, after receiving
Sumo from Uba2, Ubc9 ultimately transfers Sumo to a target.
This is often facilitated by an E3. Two types of Sumo E3s have
been structurally characterized: (1) a neither-HECT-nor-RING
E3, as in RanBP2/Nup358, which binds both Ubc9 and its
covalently-linked Sumo to optimally orient the thioester bond for
Sumo transfer to a substrate Lys [24,43,44], and (2) Siz/PIAS
E3s, which contain a SP-RING domain that structurally
resembles RING E3s utilized by the ubiquitin and NEDD8
pathway [25,45]. To gain insights into how Sumo E1-E2-E3-target
cascades are organized, we superimposed Ubc9 from our
Uba2
ufd-Ubc9 structure with that in the prior crystal structure of
Figure 3. Specificity of E1
ufd-E2 interactions. (A) Structure of isolated S. cerevisiae Uba2
ufd, shown in magenta. (B) Structure of isolated S.
cerevisiae Uba2
ufd superimposed on the corresponding region of human Uba2 (1Y8Q.pdb, blue) [19]. (C) Structure of isolated S. cerevisiae Uba2
ufd
superimposed on the corresponding region of S. cerevisiae Uba1, the E1 for ubiquitin (3CMM.pdb, green) [28]. (D) Structure of isolated S. cerevisiae
Uba2
ufd superimposed on the corresponding region of human Uba3 (1Y8X.pdb, peach) [31]. (E) Comparison of E1-E2 interactions in Sumo and
NEDD8 pathways by superimposing the E1 ufds from the Uba2
ufd–Ubc9 complex structure with a prior human Uba3
ufd-Ubc12 (grey) structure
(1Y8X.pdb) [31]. (F) Comparison of E1-E2 interactions in Sumo and NEDD8 pathways by superimposing the E1 ufds from the Uba2
ufd–Ubc9 complex
structure with a prior human Uba3
ufd-UBE2F (grey) structure (3FN1.pdb) [33].
doi:10.1371/journal.pone.0015805.g003
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structural model of Ubc9-Siz1 based on other E2-RING domain
structures [25,46]. Uba2
ufd and RanBP2/Nup358 bind overlap-
ping surfaces on Ubc9 [24] (Figure 5A). Structural modeling also
indicates that Uba2
ufd would clash with the Siz1 SP-CTD domain,
which is C-terminal of the SP-RING domain and is conserved
among Siz/PIAS E3s (Figure 5B) [25]. Thus, Uba2-mediated
formation of a Ubc9,Sumo thioester conjugate may be mutually
exclusive with E3-mediated Sumo ligation to targets.
Sumo also binds noncovalently to Ubc9, via the ‘‘backside’’ distal
from the E2 catalytic cysteine [47,48,49]. This interaction is
conserved from yeast to humans [47,48,49]. Although the function
of this noncovalent Ubc9-Sumo interaction is not well understood,
mutant versions of Ubc9 where this interaction is disrupted cannot
support yeast viability [47], and are impaired at generating long
poly-Sumo chains [48,49]. Previous biochemical data showed that
thenoncovalentSumointeraction competeswithUbc9’sinteraction
with Uba2 [37,47]. Indeed, superposition of Ubc9 from our
complex with Uba2
ufdwith priorstructuresofcomplexeswithSumo
reveal mutually exclusive binding to Ubc9’s a-helix1, particularly
Arg13 and Arg17 (Figure 5C). Thus, the Uba2
ufd recognizes
multipurpose binding sites on Ubc9, which may serve to order
association with many different partners in the Sumo cascade.
In a related vein, human Ubc9 is distinct from yeast Ubc9 in
becoming modified on Lys14 via an isopeptide bond to human
Sumo, forming a covalent complex referred to as Ubc9*Sumo
[50]. Ubc9*Sumo can bind E1 and form a thioester-linked
complex to another Sumo at its active site, which subsequently
can be transferred to targets. Sumoylation of Ubc9 shifts its
E3-independent target specificity [50]. For the substrate Sp100, it
seems Sp100’s Sumo-interacting motif (SIM) is recruited to the
Sumo linked to Ubc9’s Lys14. Comparison of the crystal structure
of human Ubc9*Sumo with that of yeast Uba2
ufd-Ubc9 reveals
that Uba2 overlaps the position of Sumo in the covalent complex
(Figure 5D). How then might human Ubc9*Sumo bind Uba2 to
become charged with Sumo? Given the high structural similarity
between human and yeast Ubc9 [40] and Uba2
ufd (Figure 3), and
prior NMR and mutational data consistent with conservation of
our structurally-observed Uba2
ufd-Ubc9 interactions in their
human counterparts [19,36,51], it seems likely that human
Uba2 and Ubc9 interact as in our structure. A plausible model
would be that there is some flexibility between Ubc9 and Sumo in
Ubc9*Sumo such that Sumo’s b-grasp domain moves out of the
way when Uba2 binds. This is consistent with ,4-fold more
human Aos1-Uba2 being required to fully bind Ubc9*Sumo in
comparison to Ubc9 in a qualitative interaction study [50].
Additional interactions might stabilize Uba2-Ubc9 complex
formation during the transthiolation reaction. Indeed, although
quantitative enzyme kinetic comparison was not performed, under
some conditions Ubc9 and Ubc9*Sumo show equal formation of
thioester-linked intermediates with Sumo [50]. Future studies will
be required to understand the dynamics of interactions between
Sumo, Ubc9, Uba2, and E3s in transfer cascades.
Conclusions
The structure of the yeast Uba2
ufd in complex with Ubc9
provides the first crystallographic insights into E1-E2 contacts in a
Figure 4. Implications of Uba2
ufd–Ubc9 structure for Smt3 transfer from Uba2 to Ubc9. (A) Structure of S. cerevisiae Uba2
ufd–Ubc9
(magenta, cyan), with Uba2
ufd superimposed on the corresponding region of human Uba2 from the Sae1-Uba2-Sumo1,AMSN complex (3KYC.pdb)
[20]. Sae1 is shown in slate, human Uba2 is shown in purple, and Sumo,AMSN is not shown for simplification. Catalytic cysteine residues of Ubc9 and
Uba2 are shown in green. (B) Autoradiograms monitoring
32P-labeled Sumo, for time-courses of Aos1-Uba2-catalyzed generation of Ubc9, [
32P]-
Sumo thioester conjugate. WT – wild-type; Uba2 C177A – cysteine-to-alanine mutation at Uba2 catalytic Cys177. Uba2 D488A,D490A – aspartate-to-
alanine mutation at Uba2’s Ubc9-interacting Asp488 and Asp490. (C) Structure of S. cerevisiae Uba2
ufd–Ubc9 (magenta, cyan), with Uba2
ufd
superimposed on the corresponding region of human Uba3 (peach) from the APPBP1 (blue) -Uba3,NEDD8-NEDD8-Ubc12(C/A)-MgATP complex
[32]. For simplification, the NEDD8 molecules are not shown, and the E2 active site positions (an Ala mutation in Ubc12) are labeled with green
spheres, and ‘‘Cys’’ to denote their locations.
doi:10.1371/journal.pone.0015805.g004
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presented previously and herein, which validate these interactions
for Sumo conjugation to Ubc9 [19,30,36,37,40,51].
The complex structure also provides only the second detailed
view of E1
ufd-E2 interactions for any UBL, and demonstrates a
common overall mode of E2 recruitment by E1 ufds: a ufd’s ‘‘W’’
(i.e., double-‘‘V’’) -shaped surface engages an E2’s N-terminal
helix and b1b2-loop. Specificity within the Sumo pathway is
established by many unique favorable interactions between Uba2
and Ubc9. Furthermore, Ubc9 is distinct among E2s as having an
extended rigid b1b2-loop. This is recognized by a conserved C-
terminal ‘‘V’’ from Uba2
ufd, comprised of Uba2 elements
spanning from b-strand23 through a-helix37. The Uba2
ufd C-
terminal ‘‘V’’ is minimized relative to the corresponding regions in
ubiquitin and NEDD8 E1s [27,28], which would be unable to
accommodate the Ubc9 b1b2-loop. Structural comparison to
Ubc9-E3 structures/models, and to Ubc9-Sumo, demonstrates
how E1-E2 interactions are mutually exclusive with forming E2-
E3 or noncovalent E2-UBL complexes in Sumo cascades.
Finally, docking the Uba2
ufd-Ubc9 structure on prior structures
of full-length Uba2 indicate that the Uba2 ufd would need to
undergo significant rotation so that the Uba2 and Ubc9 cysteines
could face each other. This is also a common feature of previous
structures from the NEDD8 cascade [27,31,32,52]. Furthermore,
based on conformational changes observed for Uba2 at earlier
steps in the Sumo activation cycle, it seems that the Uba2 cysteine
domain may also undergo conformational changes to meet the
Ubc9 cysteine for Sumo transfer [20]. Along these lines, it is
noteworthy that unique features to Uba2s and Ubc9s also establish
a distinct orientation of the E2 catalytic cysteine relative to the
E1’s E2-binding ufd (Figure 3E, Figure 3F). It will be interesting
in the future to understand how UBL-specific E1 conformational
changes accommodate such distinct geometries during E1-to-E2
UBL transfer.
Materials and Methods
Cloning, protein expression and purification
Expression constructs were made by standard PCR/ligation
procedures, with sequences verified by automated sequencing
procedures. Yeast Sumo, Smt3, is referred to as Sumo in the text.
For biochemical studies, Smt3/Sumo residues 13–97 were
expressed from pGEX-2TK (GE), harboring an N-terminal site
for phosphorylation by Protein Kinase A (PKA), and was purified
as previously described for other UBLs [33].
Uba2
ufd (residues 439–563) was expressed from pGEX-4T1
(GE). BL21(DE3) harboring the expression construct were grown
in LB with ampicillin (100 mg/mL) at 37uC until reaching an
OD600 of ,1.0. Expression was induced by the addition of IPTG
to a final concentration of 0.6 mM, followed by overnight
culturing at room temperature. Cells were resuspended in
50 mM Tris-HCl, 0.2 M NaCl, 5 mM DTT, pH 8.0 supple-
mented with 2.5 mM with PMSF, and lysed by sonication on ice.
GST-Uba2
ufd was purified by glutathione-affinity chromatogra-
phy, treated with a 1:100 ratio of thrombin during overnight
dialysis into 25 mM Tris-HCl, 0.2 M NaCl, 5 mM DTT, pH 8.0
at 4uC overnight. GST and any remaining GST-Uba2
ufd fusion
protein were removed by glutathione-affinity. For co-crystalliza-
tion, Uba2
ufd was purified by gel filtration chromatography using a
SD75 column (GE) in 25 mM Tris-HCl, 0.15 M NaCl, 5 mM
DTT, pH 7.6, concentrated to 22 mg/ml (Bio-Rad Protein
Assay), aliquotted, flash-frozen in liquid nitrogen, and stored at
280uC until further use. For crystallization on its own, Uba2
ufd
prepared similarly, except that gel filtration was performed in
50 mM Tris-HCl, 0.2 M NaCl, 5 mM DTT, pH 7.6, and
Uba2
ufd was concentrated to 40 mg/ml.
Ubc9 was expressed from pGEX4T3 (GE) [37] in BL21
(DE3) Gold cells. After growth at 37uC until the OD660 reached
,0.8, expression was induced by the addition of 1 mL of 0.6 M
Figure 5. Implications of Uba2
ufd–Ubc9 structure for Sumo cascades. (A) Comparison of E1-E2 and E2-E3 interactions in Sumo cascades.
Structure of S. cerevisiae Uba2
ufd–Ubc9 (magenta, cyan), with Ubc9 superimposed on the previous structure of human Ubc9 (cyan) bound to RanBP2/
Nup358 (olive) from the complex with RanGAP-1 (not shown) and Sumo-1 (not shown) [24]. Uba2
ufd and a portion of RanBP2/Nup358 are shown with
a semi-transparent surface to highlight the overlapping regions. (B) Structure of S. cerevisiae Uba2
ufd–Ubc9 (magenta, cyan), with Ubc9 superimposed
on a model for S. cerevisiae Ubc9-Siz1 (olive), based on previous structures of Siz1 and c-Cbl-UbcH7 [25,46]. Briefly, the RING domain c-Cbl and UbcH7
were docked onto the SP-RING domain of Siz1, and then Ubc9 was modeled in place of UbcH7. Uba2
ufd and Siz1 are shown with a semi-transparent
surface to highlight the overlapping regions. (C) Comparison of E1-E2 and noncovalent E2-UBL interactions in Sumo cascades. Structure of S.
cerevisiae Uba2
ufd–Ubc9 (magenta, cyan) superimposed in previous structure of noncovalent Ubc9-Sumo (cyan, yellow) complex from S. cerevisiae
[47]. Uba2
ufd and Sumo are shown with a semi-transparent surface to highlight the overlapping regions. (D) Structure of S. cerevisiae Uba2
ufd–Ubc9
(magenta, cyan), with Ubc9 superimposed on human Ubc9*Sumo (cyan*yellow) [50]. Uba2
ufd and Sumo are shown with a semi-transparent surface to
highlight the overlapping regions.
doi:10.1371/journal.pone.0015805.g005
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16uC. GST-Ubc9 was purified by glutathione affinity. For
biochemical studies, GST-Ubc9 bound to glutathione sepharose
was treated with thrombin overnight at 4uC to release wild-type
and mutant versions of Ubc9. Wild-type and mutant versions of
Ubc9 were concentrated in a final buffer of 50 mM Tris-HCl
pH 7.6, 200 mM NaCl, 1 mM DTT, aliquotted, flash-frozen, and
stored until use. For crystallography, GST-Ubc9 was treated with
a 1:30 ratio of thrombin overnight at 16uC. Ubc9 was purified to
homogeneity by cation exchange with a homemade column
packed with ResourceS resin (GE) using a NaCl gradient in
20 mM HEPES, 1 mM DTT, pH 7.0, concentrated to 27 mg/ml,
aliquotted, flash-frozen in liquid nitrogen, and stored at 280uC
until further use.
For biochemical assays, the expression construct for Sumo E1
(the heterodimeric Aos1-Uba2 complex) was described previously
[37]. BL21(DE3) Gold cells harboring the expression construct
were grown in LB with ampicillin (100 mg/mL) at 37uC until
reaching an OD600 of ,0.8. After cooling to 16uC for 45 minutes,
expression was induced by the addition of 1 mL of 0.2 M IPTG/
liter of culture, shaking overnight at 16uC. GST-Aos1-Uba2 was
purified by glutathione affinity chromatography, and eluted
protein was cleaved overnight with thrombin at 4uC. Aos1-Uba2
was further purified by anion exchange chromatography,
concentrated in a final buffer of 50 mM Tris-HCl pH 7.6,
,290 mM NaCl, 1 mM DTT, aliquotted, flash-frozen in liquid
nitrogen, and stored at 280uC until further use.
Crystallization, data collection, and structure
determination and refinement
Initial crystallization screening was performed with a Mosquito
crystallization robot (TTP Labtech) with commercial 96-well
screens. After testing several conditions (chemical and tempera-
ture) and Uba2
ufd-Ubc9 complexes (from human and yeast with
different ufd domain boundaries), crystals were obtained at 4uCi n
the Index HTS condition G2 (Hampton Research), for a 1.1:1
volume:volume mixture of Uba2
ufd at 22 mg/ml and Ubc9 at
27 mg/ml. A diffraction-quality crystal was obtained after multiple
cycles of streak-seeding into 20% (w/v) PEG3350, 0.1 M Bis-Tris
pH 5.5, 0.2 M Li2SO4, and harvested and flash-frozen in mother
liquor supplemented with 20% (v/v) glycerol. The crystals belong
to space-group P21. Data to 2.3 A ˚ resolution were obtained at the
SERCAT-ID beamline, and processed with HKL2000 [53]. Initial
models for the complex were obtained by performing molecular
replacement in the P1 space group using PHASER [54], after
searching for 4 copies of the structure of yeast Ubc9 (2GJD.pdb,
Chain A) [40] and of a polyAla model of human Uba2 residues
449–546 from 1Y8Q.pdb, Chain C [19]. One of the 4 complexes
from this solution was subsequently used as a search model to find
two Uba2
ufd–Ubc9 complexes per asymmetric unit in P21. The
model was built using Coot [55] and refined using TLS
parameters in REFMAC [56]. Due to low sequence similarity
with the human Uba2
ufd, we wished to obtain additional data to
confirm the structure in regions where side-chains were poorly
visible. We thus obtained crystals for the isolated Uba2
ufd at 4uCi n
the Ammonium Sulfate HTS condition H8 (Qiagen). After
optimization in manual trays, a crystal was obtained in 3 M
(NH4)2SO4, 1% (v/v) MPD, and harvested and flash-frozen in
3 M AmSO4, 1% (v/v) MPD, 25% (v/v) glycerol. Data to 1.6 A ˚
resolution were obtained at the SERCAT-ID beamline, and
processed with HKL2000 [53]. Examination of the data with
Phenix.xtriage indicated the space group to be I4, with nearly
perfect merohedral twinning and a twin operator of -k,-h,-l. The
structure was obtained by molecular replacement using PHASER
[54], with the Uba2
ufd from the partially-refined Uba2
ufd-Ubc9
complex structure as a search model for one molecule in the
asymmetric unit. After rebuilding using Coot [55] and refinement
including twin laws using Phenix [57], the isolated Uba2
ufd
structure was then used as a guide for final refinement of the
Uba2
ufd-Ubc9 structure. Data collection and refinement statistics
are provided in Table 1. The single Ramachandran outlier in the
high resolution Uba2
ufd structure corresponds to Gly517, with the
conformation supported by the electron density.
Assays for formation of a Ubc9,Sumo thioester
conjugate
Sumo was labeled with
32P at an N-terminal PKA site using
PKA (New England Biolabs) and [c-
32P]ATP as described
previously for other UBLs [33]. Reactions were performed at
18uC, which is the ambient room temperature for our dedicated
room for use of radioactivity, in 10 ml reaction volumes containing
50 mM Tris-HCl (pH 7.6), 5 mM ATP, 10 mM MgCl2, 2 mg/ml
BSA, 5 mM creatine phosphate, 0.3 U/ml creatine kinase, 0.3 U/
ml inorganic pyrophosphatase, 5 nM Aos1-Uba2, 250 nM Ubc9
or the indicated mutant, and 10 mM[ c-
32P]-Sumo. Reactions
were quenched at 1, 3, 10 and 30 minutes by the addition of an
equal volume of 2X SDS sample buffer, resolved on 15% SDS-
PAGE gels, dried, and exposed to film. In the assay containing
both Aos1-Uba2 (Cys177Ala) and Aos1-Uba2 (Asp488Ala and
Asp490Ala), 5 nM of both mutant E1s was used.
Supporting Information
Figure S1 Representative electron density. (A) Final 2Fo–
Fc electron density contoured at 1.4s (green mesh) is shown over
Uba2
ufd (magenta) – Ubc9 (cyan) complex. (B) Final 2Fo–Fc




Figure S2 Ubc9 binds W-shaped groove in Uba2
ufd.
Cartoon view of the overall structure of the complex, with Uba2
ufd
is shown in magenta surface and Ubc9 is shown in cyan. The W-
shaped groove in Uba2
ufd is indicated.
(TIF)
Figure S3 Effects of mutations in either yeast Uba2 or
Ubc9 on forming the thioester-linked Ubc9,Sumo
thioester conjugate. (A) Amount of Ubc9, [
32P]Sumo
thioester formed over time. Counts were normalized by compar-
ison to the amount of the Ubc9, [
32P]Sumo reaction product
generated for wild-type Uba2 and Ubc9 enzymes at 30 minutes.
Error bars represent standard error from experiments performed
three independent times. (B) 30-minute time points for reactions
shown in A, but treated with DTT prior to SDS-PAGE.
(TIF)
Figure S4 Sequence comparisons of Ubc9, Uba2
ufd, and
corresponding regions of E2s and E1s for other UBLs. (A)
Sequence alignment of Saccharomyces cerevisiae Ubc9 sequence (Sc),
with Ubc9 from human (Hs), and the catalytic core domain regions
ofthehumanE2sforNEDD8(Ubc12andUBE2F).Sequenceswere
aligned based on structures. Secondary structures are indicated
above. (B) Sequence alignment of Saccharomyces cerevisiae Uba2
ufd
sequence (Sc), with the corresponding regions of Uba2 from human
(Hs), and the ufds from E1s for ubiquitin (Uba1) and NEDD8
(Uba3). Sequences were aligned based on structures. Secondary
structures from the Sc Uba2
ufd structure are indicated above.
(TIF)
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